

Carla L Alves

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8266466/publications.pdf>

Version: 2024-02-01

7
papers

198
citations

1684188

5
h-index

1588992

8
g-index

8
all docs

8
docs citations

8
times ranked

266
citing authors

#	ARTICLE	IF	CITATIONS
1	MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit. <i>Npj Breast Cancer</i> , 2021, 7, 2.	5.2	7
2	Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer. <i>Breast Cancer Research</i> , 2021, 23, 26.	5.0	19
3	Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer. <i>Nature Communications</i> , 2021, 12, 5112.	12.8	38
4	Resistance Mechanisms to Combined CDK4/6 Inhibitors and Endocrine Therapy in ER+/HER2 ⁻ Advanced Breast Cancer: Biomarkers and Potential Novel Treatment Strategies. <i>Cancers</i> , 2021, 13, 5397.	3.7	7
5	SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 60.	5.0	36
6	Integrative analysis of miRNA and gene expression reveals regulatory networks in tamoxifen-resistant breast cancer. <i>Oncotarget</i> , 2016, 7, 57239-57253.	1.8	30
7	High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor ⁺ Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 5514-5526.	7.0	57